gsk1120212

Neurofibromatosis Type 1

Novartis PharmaceuticalsPhase 4 / ApprovedActive

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

14 Active assets in the Neurofibromatosis Type 1 cohort.

Asset / Sponsor	Phase	Rating
Dabrafenib Novartis Pharmaceuticals	Phase 4	B
Evomela Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Fludarabine Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Masonic Cancer Center, University of Minnesota	Phase 2	CCC